Antifungal
- Deolate contains 250 mg terbinafine as the hydrochloride
- Deolate is available in packs of 14 tablets or 84 tablets
- Deolate is fully funded on the Pharmaceutical Schedule*
Deolate is indicated for the treatment of onychomycosis (fungal infection of the nail) caused by dermatophyte fungi, tinea capitis, and other fungal infections of the skin such as tinea corporis, tinea cruris, tinea pedis and yeast infections of the skin caused by the genus Candida (e.g. Candida albicans) where oral therapy is generally considered appropriate owing to the site, severity or extent of the infection.
Deolate tablets are for oral administration.
Please note that in contrast to topical terbinafine, oral terbinafine is not effective in pityriasis versicolor.
Deolate, PRESCRIPTION MEDICINE. The active ingredient in each Deolate tablet contains 250 mg terbinafine as the hydrochloride. Deolate 250 mg is provided in packs of 14 tablets.
The therapeautic indications of Deolate tablets include the following:
- Onychomycosis (fungal infection of the nail) caused by dermatophyte fungi.
- Tinea capitis.
- Fungal infections of the skin for the treatment of tinea corporis, tinea cruris, tinea pedis and yeast infections of the skin caused by the genus Candida (e.g. Candida albicans) where oral therapy is generally considered appropriate owing to the site, severity or extent of the infection.
Note: In contrast to topical terbinafine, oral terbinafine is not effective in pityriasis versicolor.
Deolate tablets have risks and benefits. Do not use Deolate tablets if you are allergic to terbinafine or any of the other ingredients of Deolate tablets. Discuss with your doctor if you are allergic to any dyes, preservatives, other medication or foods. Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including any medicines obtained without a prescription from your pharmacy, health store or supermarket.
Deolate tablets are for oral administration. Terbinafine is not recommended for patients with chronic or active liver disease. Before prescribing Deolate tablets, pre-existing liver disease should be assessed. Hepatotoxicity may occur in patients with and without pre-existing liver disease. Patients prescribed Deolate tablets should be warned to report immediately any symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain or jaundice, dark urine or pale stools. Patients with these symptoms should discontinue taking oral terbinafine and the patient’s liver function should be immediately evaluated.
Your doctor will inform you of the Deolate tablet dosage you will be required to take each day. Abide by all instructions given by your doctor carefully. If you experience any side effects, talk to your doctor or healthcare professional. Discuss with your doctor if you have any concerns.
Deolate tablets are fully funded. Standard doctor’s fees and pharmacy charges apply.
Distributed by REX Medical Ltd, Auckland, New Zealand.
* Please note that Deolate 250 mg 14s (Pharmacode 2522748) is to be replaced with Deolate 250mg 84s (Pharmacode 2597160). However, Deolate 250mg 14s will remain funded until the delisting date which is 1 August 2021.
